We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Gastroenterology

Metabolic Synergy: How Obesity and Diabetes Amplify Liver Disease Risk in Alpha-1 Antitrypsin Deficiency

MedXY Editorial Team•Mar 13, 2026•Gastroenterology
Hepatologyliver fibrosismetabolic syndromeThiếu Hụt Alpha-1 Antitrypsin

Highlights

The presence of diabetes mellitus in Pi*ZZ individuals is associated with a four- to six-fold increase in the prevalence of advanced liver fibrosis markers compared to those without diabetes.

Obesity and overweight status significantly elevate the risk of hepatic endpoints in AATD patients, with adjusted hazard ratios reaching as high as 3.38 for obese Pi*ZZ individuals.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Subclinical Liver Disease as a Silent Driver of Cardiovascular Risk: Insights from a Large-Scale Prospective StudySubclinical liver disease, marked by steatosis, fibrosis, and functional impairment, independently and synergistically increases cardiovascular disease risk. Incorporating non-invasive liver biomarkers could enhance CVD risk prediction andSep 15, 2026Reevaluating the Link Between Helicobacter pylori Infection and Insulin Resistance: Insights from Frequentist and Bayesian Analyses in a European CohortA comprehensive European cohort study reveals that Helicobacter pylori infection’s association with insulin resistance is confounded by socioeconomic and lifestyle factors, arguing against its independent causal role and the need forAug 25, 2026Long-Term Cardiometabolic Risks of Gestational Diabetes Mellitus Subtypes: Insights from a 10-14 Year Prospective StudyThis study reveals that distinct gestational diabetes mellitus (GDM) subtypes confer increased risks of prediabetes, diabetes, metabolic syndrome, and cardiovascular disease 10-14 years postpartum, underscoring the need for tailored long-teAug 18, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Metabolic Dysfunction Following Initiation of Androgen Receptor Pathway Inhibitors in Prostate Cancer: Clinical Implications and RisksThis study reveals a significant early onset of metabolic syndrome in men with prostate cancer treated with combined ADT and ARPI therapies, highlighting the necessity for multidisciplinary metabolic monitoring and interventions.Aug 15, 2026
Cardiovascular-Kidney-Metabolic Syndrome and Its Impact on Liver Fibrosis Progression and Liver-Related Events in MASLDThis article reviews evidence linking cardiovascular-kidney-metabolic syndrome stages to liver fibrosis severity, progression, and liver-related events in metabolic dysfunction-associated steatotic liver disease (MASLD). Higher CKM stages iAug 14, 2026
Disentangling Weight Loss-Dependent and Independent Effects of Survodutide on Liver Outcomes in MASH: Insights from a Phase 2 Mediation AnalysisThis mediation analysis of a phase 2 MASH trial reveals that survodutide improves liver inflammation and fibrosis predominantly through weight-independent mechanisms, highlighting a potential direct hepatic effect beyond weight reduction.Aug 4, 2026